← Leaderboards
Christopher Charles Moore
University Of Virginia
$2,587,971
Attributed
$4,586,126
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $682.8K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,586,126 · 3
By mechanism
U01$3,996,311 · 2
K08$589,815 · 1
Top collaborators
- Scott K Heysell8 shared
Most similar at University Of Virginia
Same institution · by research overlap
- Scott K Heysell$9,245,019
- Eric R Houpt$18,307,652
- Evan R Lamb$92,715
Others in their field
Top investigators on “Cessation Of Life”
- David R. Weir · University Of Michigan At Ann Arbor$345,522,974
- John M Lachin · George Washington University$134,302,892
- David M Nathan · Massachusetts Institute Of Technology$127,791,564
- Judith S Hochman · New York University School Of Medicine$112,898,313
- Jeffrey H Samet · Boston University Medical Campus$91,739,367
- Judith S. Currier · University Of California Los Angeles$85,330,415
Research focus
Cessation Of LifeFunctional DisorderInfectionDoseLifeAntimicrobialSepsisSerumHospitalizationClinical TrialsHospital MortalityCritical IllnessMicrobialDesignDrug KineticsAdverse Drug EventClinical Trial ParticipantAdultImmune ResponseAdmission ActivityAntitubercular AgentsAfricaAfrica South Of The SaharaHiv/Tb
Grant awards (13)
STeroids and enhanced Antibiotics for the treatment of patients in Africa with Refractory Sepsis: STARS trial$361,931
U01 · FY2025 · AI
STeroids and enhanced Antibiotics for the treatment of patients in Africa with Refractory Sepsis: STARS trial$151,200
U01 · FY2025 · AI
STeroids and enhanced Antibiotics for the treatment of patients in Africa with Refractory Sepsis: STARS trial$151,200
U01 · FY2025 · AI
A randomized clinical trial of early empiric anti-Mycobacterium tuberculosis therapy for sepsis in sub-Saharan Africa$659,026
U01 · FY2024 · AI
A randomized clinical trial of early empiric anti-Mycobacterium tuberculosis therapy for sepsis in sub-Saharan Africa$669,513
U01 · FY2023 · AI
A randomized clinical trial of early empiric anti-Mycobacterium tuberculosis therapy for sepsis in sub-Saharan Africa$657,831
U01 · FY2022 · AI
A randomized clinical trial of early empiric anti-Mycobacterium tuberculosis therapy for sepsis in sub-Saharan Africa$662,780
U01 · FY2021 · AI
A randomized clinical trial of early empiric anti-Mycobacterium tuberculosis therapy for sepsis in sub-Saharan Africa$682,830
U01 · FY2020 · AI
The effects of A2A adenosine receptor agonists in sepsis$122,283
K08 · FY2010 · AI · contact PI
The effects of A2A adenosine receptor agonists in sepsis$122,283
K08 · FY2009 · AI · contact PI
The effects of A2A adenosine receptor agonists in sepsis$122,283
K08 · FY2008 · AI · contact PI
The effects of A2A adenosine receptor agonists in sepsis$111,483
K08 · FY2007 · AI · contact PI
The effects of A2A adenosine receptor agonists in sepsis$111,483
K08 · FY2006 · AI · contact PI